Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Uncategorized
Uncategorized
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Expanding ketamine’s horizons for rare neurological disorders
atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia
The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort...
atai Life Sciences Reports Third Quarter 2022 Financial Results and Business...
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil...
atai Life Sciences Reports Third Quarter 2022 Financial Results and Business...
atai Life Sciences to Participate in November Investor Events & Healthcare...
atai Life Sciences to Announce Third Quarter 2022 Financial Results and...
atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a...
atai Life Sciences Announces R&D Day Agenda
atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial...
atai Life Sciences Announces Positive Initial Results for Phase 1 Trial...
1
2
3
...
10
Page 1 of 10
